Paclitaxel
- Generic Name
- Paclitaxel
- Brand Names
- Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H51NO14
- CAS Number
- 33069-62-4
- Unique Ingredient Identifier
- P88XT4IS4D
- Background
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
- Indication
Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
- Associated Therapies
- -
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
- Conditions
- Interventions
- First Posted Date
- 2021-07-09
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 531
- Registration Number
- NCT04956692
- Locations
- 🇫🇷
Institut Regional du Cancer de Montpellier - ICM ( Site 1003), Montpellier, Herault, France
🇺🇸St. Bernards Medical Center ( Site 0103), Jonesboro, Arkansas, United States
🇺🇸West Virginia University ( Site 0056), Morgantown, West Virginia, United States
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 862
- Registration Number
- NCT04949256
- Locations
- 🇨🇷
PROCLINICAL Pharma ( Site 0904), San José, San Jose, Costa Rica
🇨🇳Shanxi Provincial Cancer Hospital ( Site 8019), Taiyuan, Shanxi, China
🇨🇳West China Hospital of Sichuan University ( Site 8048), Chengdu, Sichuan, China
Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis
- Conditions
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Seoul St. Mary's Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT04943653
- Locations
- 🇰🇷
Gastric cancer center, Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-24
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- CanariaBio Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT04938583
- Locations
- 🇰🇷
Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of
🇰🇷Korea Anam Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
- Conditions
- Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 3
- Registration Number
- NCT04929392
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT04931342
- Locations
- 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Chipscreen Biosciences, Ltd.
- Target Recruit Count
- 454
- Registration Number
- NCT04921527
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 421
- Registration Number
- NCT04908787
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Floor Backes
- Target Recruit Count
- 2
- Registration Number
- NCT04906382
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
- Conditions
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 340
- Registration Number
- NCT04895358
- Locations
- 🇺🇸
Parkview Research Center at Parkview Regional Medical Center ( Site 0071), Fort Wayne, Indiana, United States
🇺🇸University of Illinois at Chicago ( Site 0061), Chicago, Illinois, United States
🇫🇷Institut de Cancérologie de l'Ouest ( Site 0915), ANGERS cedex 02, Maine-et-Loire, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.